Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDRNASDAQ:BBIONASDAQ:MDGLNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ABBIOBridgeBio Pharma$37.52+5.8%$34.31$21.62▼$39.54$7.12B1.152.46 million shs3.08 million shsMDGLMadrigal Pharmaceuticals$284.41+4.3%$303.13$200.63▼$377.46$6.31B-0.91382,012 shs405,097 shsVRNAVerona Pharma$84.81+0.8%$66.39$11.79▼$85.27$6.88B0.21.32 million shs1.84 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%BBIOBridgeBio Pharma+3.11%+6.36%-8.06%+5.72%+26.60%MDGLMadrigal Pharmaceuticals-1.46%+1.91%-13.57%-15.14%+15.46%VRNAVerona Pharma+4.05%+12.04%+15.63%+24.59%+596.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABBIOBridgeBio Pharma4.5018 of 5 stars4.51.00.03.92.83.30.6MDGLMadrigal Pharmaceuticals4.3142 of 5 stars3.51.00.04.62.94.20.6VRNAVerona Pharma1.5533 of 5 stars2.61.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDRAlder Biopharmaceuticals 0.00N/AN/AN/ABBIOBridgeBio Pharma 2.92Moderate Buy$57.0952.16% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$416.3346.38% UpsideVRNAVerona Pharma 3.11Buy$82.13-3.17% DownsideCurrent Analyst Ratings BreakdownLatest ALDR, BBIO, VRNA, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/30/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.004/30/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.004/30/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $72.004/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73BBIOBridgeBio Pharma$127.42M55.91N/AN/A($7.71) per share-4.87MDGLMadrigal Pharmaceuticals$317.38M19.90N/AN/A$20.53 per share13.85VRNAVerona Pharma$118.54M58.01N/AN/A$3.10 per share27.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/ABBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%7/30/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%8/6/2025 (Estimated)VRNAVerona Pharma-$54.37M-$2.00N/A2,827.00N/AN/A-79.54%-43.49%8/14/2025 (Estimated)Latest ALDR, BBIO, VRNA, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDRAlder Biopharmaceuticals1.748.948.94BBIOBridgeBio PharmaN/A4.674.67MDGLMadrigal Pharmaceuticals0.155.985.93VRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDRAlder BiopharmaceuticalsN/ABBIOBridgeBio Pharma99.85%MDGLMadrigal Pharmaceuticals98.50%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipALDRAlder Biopharmaceuticals15.40%BBIOBridgeBio Pharma18.20%MDGLMadrigal Pharmaceuticals21.50%VRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million16.84 millionOptionableVRNAVerona Pharma3081.08 million76.10 millionOptionableALDR, BBIO, VRNA, and MDGL HeadlinesRecent News About These CompaniesHennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)June 3 at 7:46 AM | marketbeat.comHamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)June 3 at 6:44 AM | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockJune 3 at 2:09 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst UpgradeJune 3 at 1:15 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst UpgradeJune 2 at 10:35 AM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC WainwrightJune 2 at 8:17 AM | marketbeat.comTwo Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)June 2 at 4:07 AM | marketbeat.com7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust CorpJune 2 at 3:14 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DEJune 1 at 3:28 AM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?June 1 at 2:45 AM | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 SharesMay 31 at 5:45 PM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in StockMay 31 at 5:45 PM | marketbeat.comDavid Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31 at 5:29 PM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 SharesMay 31 at 5:29 PM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 SharesMay 31 at 5:29 PM | marketbeat.comDavid Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31 at 5:29 PM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?May 31 at 11:42 AM | marketbeat.com10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLCMay 31 at 4:52 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in StockMay 30, 2025 | insidertrades.comJim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”May 29, 2025 | insidermonkey.comVerona Pharma (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALDR, BBIO, VRNA, and MDGL Company DescriptionsAlder Biopharmaceuticals NASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.BridgeBio Pharma NASDAQ:BBIO$37.52 +2.06 (+5.81%) Closing price 04:00 PM EasternExtended Trading$37.15 -0.37 (-0.99%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Madrigal Pharmaceuticals NASDAQ:MDGL$284.41 +11.74 (+4.31%) Closing price 04:00 PM EasternExtended Trading$281.00 -3.41 (-1.20%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Verona Pharma NASDAQ:VRNA$84.81 +0.71 (+0.84%) Closing price 04:00 PM EasternExtended Trading$84.08 -0.73 (-0.85%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
